Stockscreener 앱 받기
11.68
1.35%
-0.16
전일 마감가:
$11.84
열려 있는:
$11.88
하루 거래량:
62,728
Relative Volume:
0.67
시가총액:
$3.54B
수익:
$306.77M
순이익/손실:
$-618.38M
주가수익비율:
-5.9289
EPS:
-1.97
순현금흐름:
$-343.00M
1주 성능:
-5.96%
1개월 성능:
-10.70%
6개월 성능:
-17.69%
1년 성능:
+18.58%
1일 변동 폭
$11.61
$11.88
1주일 범위
$11.61
$12.44
52주 변동 폭
$9.08
$18.00
Alvotech Stock (ALVO) Company Profile
ALVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
11.68 | 3.54B | 306.77M | -618.38M | -343.00M | -1.97 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-09-21 | 개시 | Barclays | Equal Weight |
| 2022-09-07 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-06 | 다운그레이드 | Citigroup | Buy → Sell |
| 2022-07-26 | 개시 | Citigroup | Buy |
모두보기
Alvotech 주식(ALVO)의 최신 뉴스
Alvotech’s Eylea Biosimilar ‘Keeps In Mind’ US Patent Landscape - Citeline
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth hurdles - Investing.com
Alvotech (ALVO) Shares Gap Down to $11.94 on Nov 22 - GuruFocus.com
Alvotech’s Position In The Coming Biosimilar Gold Rush (NASDAQ:ALVO) - Seeking Alpha
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates - MSN
Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023) - Yahoo Finance
Earnings call: Alvotech reported revenues of $128 million - Investing.com India
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - Investing.com Canada
Alvotech Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call: Alvotech reported revenues of $128 million By Investing.com - Investing.com Canada
Alvotech earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Alvotech earnings missed, revenue fell short of estimates - Investing.com India
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges By Investing.com - Investing.com Australia
Alvotech : First 9 Months Earnings and Business Update 2024 - Marketscreener.com
Alvotech Showcases Strong Financial Growth and Expansion - TipRanks
Alvotech Reports Financial Results for the First Nine Months of 2024 - The Manila Times
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges - Investing.com
EMA Accepts Marketing Authorization Application for Alvotech’s AVT05 (golimumab) - JD Supra
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times
Alvotech Attending Citi's Global Healthcare Conference on - GlobeNewswire
Alvotech to Present at Citi and Evercore Healthcare Conferences in December | ALVO Stock News - StockTitan
ADVANZ PHARMAEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi - Marketscreener.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for its biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA - Pharmaceutical Technology
Alvotech application for Simponi biosimilar accepted by EMA - MSN
Alvotech’s AVT05 Biosimilar Application Accepted by EMA - TipRanks
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - The Manila Times
European Medicines Agency Confirms Acceptance of Marketing - GlobeNewswire
Alvotech and Teva Announce FDA Approval of Additional Presentation for Ustekinumab Biosimilar - JD Supra
Alvotech Petitions FDA To Deny Interchangeability For Rival Stelara Biosimilars - Citeline News & Insights
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times
Alvotech to Report Financial Results for the First Nine - GlobeNewswire
Alvotech, Teva obtain FDA nod for new Selarsdi indication - Drug Store News
Exploring High Growth Tech Stocks In The US October 2024 - Simply Wall St
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - StockTitan
Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire
FDA approves Alvotech and Teva’s SELARSDI for new indications - MSN
Alvotech's SWOT analysis: biosimilar powerhouse stock faces growth hurdles - Investing.com
Teva, Alvotech get expanded FDA approval for Stelara biosimilar - MSN
Teva, Alvotech get expanded FDA approval for Stelara biosimilar (NYSE:TEVA) - Seeking Alpha
Alvotech and Teva Secure FDA Approval for SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - The Manila Times
Teva, Alvotech announce U.S. FDA approval of presentation of SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional - GlobeNewswire
Alvotech (ALVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.83%
1.03%
자본화:
|
볼륨(24시간):